Oral Administration of MVA-Vectored Vaccines Induces Robust, Long-Lasting Neutralizing Antibody Responses and Provides Complete Protection Against SARS-CoV-2 in Mice, Minks, and Cats
Open Access
Abstract
Background/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can naturally infect a broad spectrum of animal species, with cats, minks, and ferrets being highly susceptible. There is a potential risk that infected animals could transmit viruses to humans. Moreover, SARS-CoV-2 continues to evolve via mutation and genetic recombination, resulting in the continuous emergence of new variants that have triggered a wave of reinfection. Therefore, safe and effective corona virus disease 2019 (COVID-19) vaccines for animals are still being sought. Methods: We generated three recombinant Modified vaccinia virus Ankara (MVAs) expressing the prefusion-stabilized S proteins, S6P, DS6P, and BA2S6P, targeting the full-length S protein genes of the ancestral, Delta, and Omicron BA.2 strains of SARS-CoV-2. Subsequently, the safety, immunogenicity, and protective efficacy of these MVA-based oral COVID-19 vaccine candidates were assessed in mice, minks, and cats. Results: These recombinant MVAs are safe in mice, minks, and cats. Oral or intramuscular vaccination with rMVA-S6P induced a robust SARS-CoV-2 neutralizing antibody (NA) response and conferred complete protection against the SARS-CoV-2 challenge in mice. Meanwhile, oral or intramuscular administration of these recombinant MVAs in combination induced a potent and durable NA response against homotypic SARS-CoV-2 pseudovirus in mice, minks, and cats, respectively. Conclusions: These findings suggest that the MVA-vectored vaccines are promising oral COVID-19 vaccine candidates for animals, and that the combined vaccination approach is an effective administration strategy for such vaccines.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC2604200, 2025YFC2609600)
This publication has 45 references indexed in Scilit:
- Rabies virus-based oral and inactivated vaccines protect minks against SARS-CoV-2 infection and transmission1Journal of Integrative Agriculture, 2024
- Next-generation treatments: Immunotherapy and advanced therapies for COVID-19Heliyon, 2024
- COVID-19 vaccine development: milestones, lessons and prospectsSignal Transduction and Targeted Therapy, 2022
- A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungsImmunity, 2021
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2Cell, 2020
- Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trialThe Lancet Infectious Diseases, 2020
- Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trialThe Lancet, 2020
- Current state and challenges in developing oral vaccinesAdvanced Drug Delivery Reviews, 2017
- Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trialThe Lancet Infectious Diseases, 2014
- A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicityCancer Immunology, Immunotherapy, 2000